Upstream Bio, Inc. (NASDAQ:UPB - Free Report) - Analysts at William Blair issued their Q4 2025 earnings per share (EPS) estimates for Upstream Bio in a research report issued on Thursday, November 7th. William Blair analyst M. Phipps anticipates that the company will post earnings per share of ($0.66) for the quarter. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Upstream Bio's current full-year earnings is ($5.75) per share.
UPB has been the subject of a number of other research reports. JPMorgan Chase & Co. began coverage on shares of Upstream Bio in a research report on Tuesday, November 5th. They set an "overweight" rating and a $38.00 target price for the company. TD Cowen initiated coverage on Upstream Bio in a research note on Tuesday, November 5th. They issued a "buy" rating for the company. Finally, Piper Sandler assumed coverage on Upstream Bio in a report on Tuesday, November 5th. They issued an "overweight" rating and a $75.00 price objective for the company.
Read Our Latest Analysis on Upstream Bio
NASDAQ UPB opened at $26.18 on Monday. Upstream Bio has a fifty-two week low of $20.74 and a fifty-two week high of $29.46.
In related news, major shareholder Ai Upstream Llc bought 1,175,000 shares of the firm's stock in a transaction on Tuesday, October 15th. The stock was acquired at an average cost of $17.00 per share, for a total transaction of $19,975,000.00. Following the purchase, the insider now owns 1,175,000 shares in the company, valued at approximately $19,975,000. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, major shareholder Ai Upstream Llc purchased 1,175,000 shares of the stock in a transaction that occurred on Tuesday, October 15th. The stock was bought at an average cost of $17.00 per share, for a total transaction of $19,975,000.00. Following the completion of the transaction, the insider now directly owns 1,175,000 shares in the company, valued at $19,975,000. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Erez Chimovits bought 825,000 shares of the company's stock in a transaction on Tuesday, October 15th. The stock was bought at an average price of $17.00 per share, for a total transaction of $14,025,000.00. Following the completion of the purchase, the director now directly owns 4,554,873 shares in the company, valued at approximately $77,432,841. This represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here.
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Upstream Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstream Bio wasn't on the list.
While Upstream Bio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.